ePub
Citation
Print
| Korean J Lab Med. 2010 Dec;30(6):554-558. Korean. Published online December 02, 2010. https://doi.org/10.3343/kjlm.2010.30.6.554 | |
| Copyright © 2010 The Korean Society for Laboratory Medicine | |
Seungwon Jung, M.D.,1
Jihyang Lim, M.D., 1
Byung Sik Cho, M.D.,2
Hyojin Chae, M.D.,1
Myungshin Kim, M.D.,1
Yonggoo Kim, M.D.,1
Kyungja Han, M.D.,1
Jong Wook Lee, M.D.,2
and Woo Sung Min, M.D.2
| |
|
1Department of Laboratory Medicine, The Catholic University of Korea School of Medicine, Seoul, Korea. | |
|
2Division of Hematology, Department of Internal Medicine, Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea School of Medicine, Seoul, Korea. | |
| Corresponding author: Jihyang Lim, M.D. Department of Laboratory Medicine, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Korea. Tel: +82-2-2258-1643, Fax: +82-2-2258-1719,
| |
| Received April 30, 2010; Revised September 10, 2010; Accepted October 07, 2010. | |
|
Abstract
| |
|
Background
Epstein-Barr virus (EBV) is a well-known causative agent of various diseases including post-transplant lymphoproliferative disorders. Although the level of EBV viral load in donors is expected to have a direct effect on recipients after hematopoietic stem cell transplantation (HSCT), little has been studied providing a clear evidence for that. We performed EBV DNA quantitation in donors and analyzed the effect of donors' EBV viral load on the recipients after HSCT.
Methods
EBV DNA quantitation of peripheral blood in 94 healthy HSCT donors was performed by real-time PCR. We analyzed the distribution of EBV viral load in HSCT donors and EBV positivity in the recipients transplanted from donors who had detectable EBV.
Results
Fifteen HSCT donors (16%) showed positive results in EBV real-time quantitative PCR. EBV viral load was below 500 copies/mL in 5 donors and above 500 (680-11,300) copies/mL in 10 donors. Five of the recipients (33.3%) transplanted from these 15 donors showed positivity in EBV PCR after HSCT. All of the EBV PCR positive recipients were transplanted from donors with viral load of >1,000 copies/mL, and 5 (71%) of 7 donors with viral load of >1,000 copies/mL was associated with posttansplant EBV PCR positivity in the recipients.
Conclusions
Higher levels of EBV viral load in donors appear to be associated with EBV transmission to recipients in HSCT. EBV real-time quantitative PCR may be needed for screening EBV DNA level in HSCT donors. |
|
Keywords: EBV; Real time PCR; Hematopoietic stem cell transplantation; Donor |
|
|
Tables
|
|
|
|
References
|
| 1. | Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539–546. 
|
| 2. | Schäfer H, Berger C, Aepinus C, Hebart H, Beck R, Kaiserling E, et al. Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting. Transplantation 2001;72:492–496.
|
| 3. | Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234–1243.
|
| 4. | Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72:520–529.
|
| 5. | Gratama JW, Oosterveer MA, Lepoutre J, Fibbe WE, Ringdén O, Vossen JM, et al. Epstein-Barr virus infection in allogeneic marrow grafting: lessons for transplant physicians and virologists. Ann Hematol 1992;64 S:A162–A165.
|
| 6. | Haque T, Thomas JA, Falk KI, Parratt R, Hunt BJ, Yacoub M, et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996;77:1169–1172.
|
| 7. | Lin JC, Chen KY, Wang WY, Jan JS, Liang WM, Tsai CS, et al. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol 2001;19:2607–2615.
|
| 8. | van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364–4369.
|
| 9. | Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005;56:29–44.
|
| 10. | Lange B, Henle W, Meyers JD, Yang LC, August C, Koch P, et al. Epstein-Barr virus-related serology in marrow transplant recipient. Int J Cancer 1980;26:151–157.
|
| 11. | Lee ES, Locker J, Nalesnik M, Reyes J, Jaffe R, Alashari M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995;332:19–25.
|
| 12. | Collins MH, Montone KT, Leahey AM, Hodinka RL, Salhany KE, Clark BJ, et al. Metachronous Epstein-Barr virus-related smooth muscle tumors in a child after heart transplantation: case report and review of the literature. J Pediatr Surg 2001;36:1452–1455.
|
| 13. | Bitan M, Or R, Shapira MY, Mador N, Resnick IB, Saleh N, et al. Early-onset Guillain-Barre syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation. Clin Infect Dis 2004;39:1076–1078.
|